Alcohol-induced liver disease

Clinics in Liver Disease

Volumn 4, Issue 1, 2000, Pages 115-131

  Maddrey, Willis C ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANABOLIC AGENT; CORTICOSTEROID; CYTOKINE; EPIDERMAL GROWTH FACTOR; GLUCAGON; GLUTATHIONE; INSULIN; INTERLEUKIN 6; MALOTILATE; OXANDROLONE; PARACETAMOL; PHOSPHATIDYLCHOLINE; PLATELET DERIVED GROWTH FACTOR; PREDNISOLONE; PROPYLTHIOURACIL; RETINOL; S ADENOSYLMETHIONINE; SILYMARIN; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; ANIMAL MODEL; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ALCOHOL INTERACTION; FATTY LIVER; HEPATITIS B; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; NONHUMAN; NUTRITIONAL STATUS; PATHOGENESIS; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0034424754     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1089-3261(05)70099-4     Document Type: Article

References (124)

1. Alcoholic liver disease
2. Formation of extracellular matrix in normal rat liver: Lipocytes as a major source of proteoglycan
3. A randomized clinical trial of insulin and glucagon infusion for treatment of alcoholic hepatitis: Progress report in 50 patients
4. Pathogenesis of alcohol-induced accumulation of protein in the liver
5. Prediction of risk of liver disease by alcohol intake, sex, and age: A prospective population study
6. Chronic hepatitis C in alcoholic patients: Prevalence, genotypes, and correlation to liver disease
7. Prevalence of chronic liver disease in the general population of Northern Italy: The Dionysos study
8. Time trends and age-period-cohort effects on the incidence of primary liver cancer in a well-defined French population: 1976-1995
9. Efficacy of liver transplantation for alcoholic cirrhosis with respect to recidivism and compliance
10. Insulin and glucagon infusion in acute hepatitis: A prospective randomized controlled trial
11. Increased plasma tumor necrosis factor in severe alcoholic hepatitis
12. A randomized, controlled trial of treatment of alcoholic hepatitis with parenteral nutrition and oxandrolone. I. Short-term effects on liver function
13. A randomized, controlled trial of treatment of alcoholic hepatitis with parenteral nutrition and oxandrolone. II. Short-term effects on nitrogen metabolism, metabolic balance and nutrition
14. Genetic factors in alcohol metabolism and alcoholism
15. Mechanisms of hepatic toxicity: I. TNF-induced liver injury
16. Serological and histological aspects of hepatitis C virus infection in alcoholic patients
17. Methylprednisolone therapy in patients with severe alcoholic hepatitis: A randomized multicenter trial
18. Cell-mediated hepatic injury in alcoholic liver disease
19. Hepatitis C virus in alcoholic patients with and without clinically apparent liver disease
20. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis
21. Chronic hepatitis C: Effect of alcohol on hepatic activity and viral titre
22. Chronic ethanol administration impairs receptor-mediated endocytosis of epidermal growth factor by rat hepatocytes
23. Alcoholic liver disease: Dose and threshold-new thoughts on an old topic
24. IgA triggers tumor necrosis factor and secretion by monocytes: A study in normal subjects and patients with alcoholic cirrhosis
25. Alcoholic liver disease: Natural history
26. Alcohol-related trafficking accidents
27. Effect of parenteral amino acid supplementation in alcoholic hepatitis
28. The effect of chronic ethanol feeding on ornithine decarboxylase activity and liver regeneration
29. Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: A case-control study in Italy
30. Rising incidence of hepatocellular carcinoma in the United States
31. A prospective multicenter study of insulin and glucagon infusion therapy in acute alcoholic hepatitis
32. The nonefficacy of short-term anabolic steroid therapy in alcoholic liver disease
33. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver
34. Clinical significance of concomitant hepatitis C infection in patients with alcoholic liver disease
35. Pathology of alcoholic liver disease
36. The cellular basis of hepatic fibrosis: Mechanisms and treatment strategies
37. Hepatic fibrosis
38. Closing in on the signals of hepatic fibrosis
39. Inhibitory effects of chronic ethanol consumption on cellular immune responses to hepatitis C virus core protein are reversed by genetic immunizations augmented with cytokine-expressing plasmids
40. Liver transplantation for patients with alcoholism and end-stage liver disease
41. Double-blind, controlled trial of propylthiouracil in severe acute alcoholic hepatitis
42. Alcoholic steatonecrosis: Relationship between severity of hepatic disease and presence of Mallory bodies in the liver
43. Increased plasma interleukin-6 activity in alcoholic hepatitis
44. Alcoholic liver injury: Defenestration in noncirrhotic livers. A scanning electron microscopic study
45. Early alcoholic liver injury: Changes of the Disse space in acinar zone 3
46. Early alcoholic liver injury. Activation of lipocytes in acinar zone 3 and correlation to degree of collagen formation in the Disse space
47. A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis
48. Do corticosteroids reduce mortality from alcoholic hepatitis?
49. The increasing incidence of hepatocellular carcinoma
50. Stimulation of monocyte interleukin-8 by lipid peroxidation products: A mechanism for alcohol-induced liver injury
51. Effects of dexamethasone on albumin and collagen gene expression in primary cultures of adult rat hepatocytes
52. Decreased hepatic glutathione in chronic alcoholic patients
53. Milestones in liver transplantation for alcoholic liver disease
54. High malignancy of hepatocellular carcinoma in alcoholic patients with hepatitis C virus
55. Orthotopic liver transplantation for alcoholic liver disease
56. Hormonal control of rat liver regeneration
57. Quantitative aspects of drinking in alcoholic liver cirrhosis
58. Polyunsaturated lecithin prevents acetaldehyde-mediated hepatic collagen accumulation by stimulating collagenase activity in cultured lipocytes
59. Hepatic and other medical disorders of alcoholism: From pathogenesis to treatment
60. S-adenosyl-L-methionine attenuates alcoholinduced liver injury in the baboon
61. Polyenylphosphatidylcholine decreases alcoholinduced oxidative stress in the baboon
62. Phosphatidylcholine protects against fibrosis and cirrhosis in the baboon
63. Selection for and outcome of liver transplantation in alcoholic liver disease
64. Histologic spectrum of alcoholic liver disease
65. Is therapy with testosterone or anabolic-androgenic steroids useful in the treatment of alcoholic liver disease?
66. Alcoholic hepatitis: Pathogenesis and approaches to treatment
67. Alcohol and the liver: An overview
68. Corticosteroid therapy of alcoholic hepatitis
69. Lipocytes and transitional cells in alcoholic liver disease: A morphometric study
70. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone
71. S-adenosylmethionine in the treatment of alcoholic liver cirrhosis: Results from a multicentric, placebo-controlled, randomized, doubleblind clinical trial
72. Cytokines and alcoholic liver disease
73. Tumor necrosis factor and alcoholic liver disease
74. Alcoholic liver disease
75. Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone
76. A study of oral nutritional support with oxandrolone in malnourished patients with alcoholic hepatitis: Results of a Department of Veterans Affairs cooperative study
77. Antibodies to hepatitis B virus and hepatitis C virus in alcoholic hepatitis and cirrhosis: Their prevalence and clinical relevance
78. Interaction between alcohol and nutrition in the pathogenesis of alcohol liver disease
79. Hepatitis B antibody in alcoholic cirrhosis
80. Effect of alcohol intake on the efficacy of interferon therapy in patients with chronic hepatitis C as evaluated by multivariate logistic regression analysis
81. Nutritional therapies in liver disease
82. Hepatitis C viremia and anti-HCV antibodies in alcoholics
83. Intestinal endotoxins as mediators of hepatic injury-an idea whose time has come again
84. Efficacy of interferon therapy in patients with chronic hepatitis C
85. Molecular regulation of hepatic fibrogenesis
86. Long-term treatment of alcoholic liver disease with propylthiouracil
87. Reliability of assessment of alcohol intake based on personal interviews in a liver clinic
88. Effect of short-term therapy with propylthiouracil in patients with alcoholic liver disease
89. Hepatitis C virus antibodies in chronic alcoholic patients: Association with severity of liver injury
90. Effects of silymarin in alcoholic patients with cirrhosis of the liver: Results of a controlled, double-blind, randomized and mulficenter trial
91. Immunologic reactions in alcoholic liver disease
92. Increased risk of liver cirrhosis with intake of alcohol
93. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C
94. Independent risk factors for hepatocellular carcinoma in French drinkers
95. Evaluation of efficacy of liver transplantation in alcoholic cirrhosis by a case-control study and simulated controls
96. Natural history of liver fibrosis progression in patients with chronic hepatitis C
97. A randomized trial of prednisolone in patients with severe alcoholic hepatitis
98. Alcohol consumption enhances intrahepatic hepatitis C virus replication
99. Carbohydrate-deficient transferrin as a marker of alcohol consumption in male patients with liver disease
100. Nutrient intake and nutritional status in alcoholics
101. Medical consequences of alcohol abuse: Is gender a factor?
102. Should patients with end-stage alcoholic liver disease have a new liver?
103. Hepatitis C and alcohol
104. Acetaminophen hepatotoxicity in alcoholics
105. Serum secretory IgA and secretory component in patients with non-cirrhotic alcoholic liver diseases
106. Risk factors for cirrhosis in patients with chronic hepatitis C virus infection: Results of a case-control study
107. Survival and quality of life after liver transplantation for acute alcoholic hepatitis
108. Liver transplantation for alcoholic liver disease
109. Circulating and tissue levels of the neutrophil chemotaxin interleukin-8 are elevated in severe acute alcoholic hepatitis, and tissue levels correlate with neutrophil infiltration
110. Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis
111. Orthotopic liver transplantation for alcoholic cirrhosis
112. Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon: A multicenter sequential trial
113. The intralobular distribution of ethanolinducible P450IIE1 in rat and human liver
114. Effects of ethanol on protein trafficking in the liver
115. The characteristics of alcoholic liver disease in Japan. Clinicopathologic comparison with alcoholic liver disease in the United States
116. Immunoglobulin A in the diagnosis of alcohol liver disease
117. Early perivenular sclerosis in alcoholic fatty liver: An index of progressive liver injury
118. Sinusoidal caliber in alcoholic and nonalcoholic liver disease: Diagnostic and pathogenic implications
119. Transcriptional and posttranscriptional effects of dexamethasone on albumin and procollagen messenger RNAs in murine schistosomiasis
120. Ito-cell gene expression and collagen regulation
121. Impact of alcohol on the histological and clinical progression of hepatitis C infection
122. Perivenular fibrosis as precursor lesion of cirrhosis
123. Alcoholic hepatitis. Cell-mediated immunological response to alcoholic hyaline
124. Acetaminophen hepatotoxicity in alcoholics